Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$1.89 USD
-0.02 (-1.05%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $1.88 -0.01 (-0.53%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Immix Biopharma, Inc. [IMMX]
Reports for Purchase
Showing records 1 - 20 ( 54 total )
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
US$8m grant to advance novel CAR-T treatment
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
US CAR-T trial commences patient dosing
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Advancing Cell Therapy With the N-GENIUS Platform; Initiating at Buy $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Reaffirmed long-term focus on outpatient CAR-T
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Marching towards US clinical trials for NXC-201
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
2023 recap with a preview of active year ahead
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Updates galore: NXC-201 ODD (EU) and raise
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Increased legroom following common-only raise
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging stream of ALA data newsflow
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
100% ORR Continues for NXC-201 in ALA, 10 Patients Evaluated Thus Far
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Underscores Unmet ALA Need NXC-201''s Potential & Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
CAR-T trial moves to US with outpatient potential
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
A quarter of progress for both lead assets
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
A step toward delivering a practical CAR-T option
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S